Personalis FY2024 EPS Forecast Decreased by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Investment analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Personalis in a research note issued on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.37) per share for the year, down from their previous forecast of ($1.01). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.46) EPS and FY2027 earnings at ($0.04) EPS.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The company had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same quarter in the prior year, the firm posted ($0.51) EPS.

A number of other research firms have also recently commented on PSNL. Needham & Company LLC reiterated a “buy” rating and set a $7.25 target price on shares of Personalis in a research report on Thursday, November 7th. BTIG Research lifted their price target on Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research report on Friday, August 16th.

Personalis Price Performance

Shares of PSNL opened at $5.23 on Monday. Personalis has a 1-year low of $1.00 and a 1-year high of $7.20. The stock has a market cap of $277.61 million, a PE ratio of -3.11 and a beta of 1.94. The firm has a fifty day moving average price of $5.12 and a 200 day moving average price of $3.42.

Institutional Investors Weigh In On Personalis

Institutional investors and hedge funds have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Personalis by 98.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 108,788 shares of the company’s stock worth $585,000 after buying an additional 53,965 shares during the last quarter. ARK Investment Management LLC lifted its position in Personalis by 11.4% during the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after acquiring an additional 723,637 shares during the period. Semanteon Capital Management LP purchased a new position in shares of Personalis in the 3rd quarter valued at approximately $375,000. International Assets Investment Management LLC increased its holdings in shares of Personalis by 438.0% in the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after purchasing an additional 17,082 shares during the period. Finally, nVerses Capital LLC purchased a new stake in shares of Personalis during the third quarter worth approximately $40,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.